Skip to main content

Advertisement

Table 2 Outcome of the 36 children with philadelphia chromosome-positive acute lymphoblastic leukemia as a function of early characteristics

From: Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study

  No patients No CR (%) p 5 yr-EFS p 5 yr-OS p
Whole cohort N = 36 26 (72%)   33.3 ± 7.9   47.2 ± 8.3  
Inclusion period        
< July, 1996 15 9 (60%)   20 ± 10   33 ± 12  
> July, 1996 21 17 (81%) 0.26 43 ± 11 0.13 57 ± 11 0.31
Age (years)        
<10 23 20 (87%)   48 ± 10   61 ± 10  
≥ 10 13 6 (46%) 0.018 15 ± 10 0.01 23 ± 12 0.006
WBC (/mm 3 )        
<50,000 21 17 (81%)   33 ± 10    
≥ 50,000 15 9 (60%) 0.26 33 ± 12 0.54   0.91
<100,000 26 22 (85%)   42 ± 10   58 ± 10  
≥ 100,000 10 4 (40%) 0.014 10 ± 9 0.003 20 ± 13 0.03
Response to steroid (+3 drug intra-thecal injection) at D8        
poor (≥ 1000 blasts/mm3) 5 2 (40%)   20 ± 18   20 ± 18  
good(<1000 blasts/mm3) 31 24 (77%) 0.12 35 ± 9 0.33 52 ± 9 0.19
Response to chemotherapy evaluated on D21        
M1(≤ 5% blasts) 21 20 (95%)   43 ± 11   62 ± 11  
M2+M3 (>5%–25% and >25% blasts) 15 6 (40%) 0.0004 20 ± 10 0.18 27 ± 11 0.06
Age, D21 response and WBC        
Age<10 and D21 M1 and WBC count<100,000 14 14 (100%)   57 ± 13   79 ± 11  
Others 22 12 (55%) 0.003 18 ± 8 0.002 27 ± 9 0.003
  1. WBC = white blood cell; D = day; Response to steroid is evaluated in peripheral blood on day 8; Response to chemotherapy is evaluated in bone marrow on day 21